A federal budget proposal to transition into a National Pharmacare framework has the potential to further shake-up the market.

Public and private payers are looking to harness innovative solutions to ensure plan sustainability, lessen the financial burden on the healthcare system and improve patient outcomes. Precision medicine holds significant potential to strengthen a value based approach. However, it remains largely unclear how the implementation of a Canadian Pharmacare system would address the patchwork of coverage and cost of advanced therapeutics. In this evolving landscape, manufacturers will be required to optimize HTA submissions and commercialization strategies through increased collaboration with stakeholders.
View the Agenda and Speaker Faculty.

Hear from a distinguished faculty:

2019 CO-CHAIRS

Nathaniel Lipkus Partner Osler Hoskin & Harcourt LLP
Alexis Sciuk Director, Access and Government Relations, Ontario and Private Sector Pfizer Canada Inc.

SPEAKERS

Sylvie Bouchard Director of Medication INESSS
Mathew Brougham CEO & Principal Consultant Brougham Consulting Inc.
Kobina Quansah Outcomes Research Manager Boehringer Ingelheim (Canada) Ltd
Brent Fraser Vice President Pharmaceutical Reviews CADTH
Sang Mi Lee Senior Pharmacist Pan-Canadian Pharmaceutical Alliance
Vincenzo Ciampi Executive Director, Innovation and Strategic Projects Sandoz Canada

Prepare for the future of market entry through open dialogue about:
  • OPERATING within the proposed National Pharmacare system in Canada
  • UTILIZING RWE to bolster submissions as well as access and reimbursement strategies
  • LEVERAGING new platforms to speed up start times on clinical trials and streamline the associated approvals for market access
  • ASSESSING the impact of the proposed PMPRB plan to lower the pricing ceiling on manufacturers from R&D to market entry
  • HONING your approach to negotiations with pan-Canadian Pharmaceutical Alliance (pCPA) on advanced therapeutics
  • UNDERSTANDING how rising pressures for affordable treatment and the potential for interchangeability could support new inroads for biosimilars
  • ANALYZING developments in precision medicine that could increase safety and efficacy of treatments while reducing healthcare spending